Monte Rosa Therapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Monte Rosa Therapeutics (NASDAQ:GLUE) reported Q4 earnings with an EPS of $-0.58, missing estimates by -76.0% and showing no revenue change from the previous year. Last quarter, the company beat EPS estimates which was followed by a 3.0% drop in share price.
March 14, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Monte Rosa Therapeutics reported a significant miss in Q4 earnings with an EPS of $-0.58, underperforming estimates by -76%, and no revenue growth from the previous year.
The significant miss in earnings estimates and the lack of revenue growth are likely to negatively impact investor sentiment and could lead to a decrease in stock price, similar to the 3.0% drop observed after last quarter's earnings beat.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100